Annual report
9265.TEDINET S100YXFY
Period2025-06-01 → 2026-05-31
Filed2026-08-25
StandardJapan GAAP
ConsolidatedYes
Data checks24 of 24 passed
Key figures · 148
| Metric | Value | Period | Scope | Source row |
|---|---|---|---|---|
| Revenue | ¥64.1bn | 2025-06-01 → 2026-05-31 | Cons. | Net sales |
| Revenue | ¥64.5bn | 2024-06-01 → 2025-05-31 | Cons. | Net sales |
| Revenue | ¥61.6bn | 2023-06-01 → 2024-05-31v | Cons. | Net sales (5-year summary) |
| Revenue | ¥58.2bn | 2022-06-01 → 2023-05-31v | Cons. | Net sales (5-year summary) |
| Revenue | ¥55.1bn | 2021-06-01 → 2022-05-31v | Cons. | Net sales (5-year summary) |
| Operating income | ¥737m | 2025-06-01 → 2026-05-31 | Cons. | Operating income |
| Operating income | ¥838m | 2024-06-01 → 2025-05-31 | Cons. | Operating income |
| Ordinary income | ¥877m | 2025-06-01 → 2026-05-31 | Cons. | Ordinary income |
| Ordinary income | ¥909m | 2024-06-01 → 2025-05-31 | Cons. | Ordinary income |
| Ordinary income | ¥1.0bn | 2023-06-01 → 2024-05-31v | Cons. | Ordinary income loss (5-year summary) |
| Ordinary income | ¥1.2bn | 2022-06-01 → 2023-05-31v | Cons. | Ordinary income loss (5-year summary) |
| Ordinary income | ¥1.0bn | 2021-06-01 → 2022-05-31v | Cons. | Ordinary income loss (5-year summary) |
| Profit before tax | ¥929m | 2025-06-01 → 2026-05-31 | Cons. | Income before income taxes |
| Profit before tax | ¥943m | 2024-06-01 → 2025-05-31 | Cons. | Income before income taxes |
| Net income (owners) | ¥648m | 2025-06-01 → 2026-05-31 | Cons. | Profit loss attributable to owners of parent |
| Net income (owners) | ¥616m | 2024-06-01 → 2025-05-31 | Cons. | Profit loss attributable to owners of parent |
| Net income (owners) | ¥580m | 2023-06-01 → 2024-05-31v | Cons. | Profit loss attributable to owners of parent (5-year summary) |
| Net income (owners) | ¥219m | 2022-06-01 → 2023-05-31v | Cons. | Profit loss attributable to owners of parent (5-year summary) |
| Net income (owners) | ¥696m | 2021-06-01 → 2022-05-31v | Cons. | Profit loss attributable to owners of parent (5-year summary) |
| Net income | ¥647m | 2025-06-01 → 2026-05-31 | Cons. | Profit loss |
| Net income | ¥614m | 2024-06-01 → 2025-05-31 | Cons. | Profit loss |
| Total assets | ¥27.1bn | at 2026-05-31 | Cons. | Assets |
| Total assets | ¥27.5bn | at 2025-05-31 | Cons. | Assets |
| Total assets | ¥26.6bn | at 2024-05-31v | Cons. | Total assets (5-year summary) |
| Total assets | ¥24.6bn | at 2023-05-31v | Cons. | Total assets (5-year summary) |
| Total assets | ¥24.1bn | at 2022-05-31v | Cons. | Total assets (5-year summary) |
| Total liabilities | ¥17.7bn | at 2026-05-31 | Cons. | Liabilities |
| Total liabilities | ¥18.6bn | at 2025-05-31 | Cons. | Liabilities |
| Net assets / equity | ¥9.4bn | at 2026-05-31 | Cons. | Net assets |
| Net assets / equity | ¥9.0bn | at 2025-05-31 | Cons. | Net assets |
| Net assets / equity | ¥8.6bn | at 2024-05-31v | Cons. | Net assets |
| Net assets / equity | ¥7.9bn | at 2023-05-31v | Cons. | Net assets (5-year summary) |
| Net assets / equity | ¥8.0bn | at 2022-05-31v | Cons. | Net assets (5-year summary) |
| Cash and deposits | ¥4.1bn | at 2026-05-31 | Cons. | Cash and deposits |
| Cash and deposits | ¥5.7bn | at 2025-05-31 | Cons. | Cash and deposits |
| Cash & equivalents | ¥4.1bn | at 2026-05-31 | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥5.7bn | at 2025-05-31 | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥5.3bn | at 2024-05-31v | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥5.8bn | at 2023-05-31v | Cons. | Cash and cash equivalents (5-year summary) |
| Cash & equivalents | ¥4.0bn | at 2022-05-31v | Cons. | Cash and cash equivalents (5-year summary) |
| Operating cash flow | ¥88m | 2025-06-01 → 2026-05-31 | Cons. | Net cash provided by used in operating activities |
| Operating cash flow | ¥617m | 2024-06-01 → 2025-05-31 | Cons. | Net cash provided by used in operating activities |
| Operating cash flow | ¥878m | 2023-06-01 → 2024-05-31v | Cons. | Net cash provided by used in operating activities (5-year summary) |
| Operating cash flow | ¥2.2bn | 2022-06-01 → 2023-05-31v | Cons. | Net cash provided by used in operating activities (5-year summary) |
| Operating cash flow | ¥581m | 2021-06-01 → 2022-05-31v | Cons. | Net cash provided by used in operating activities (5-year summary) |
| Investing cash flow | −¥1.3bn | 2025-06-01 → 2026-05-31 | Cons. | Net cash provided by used in investment activities |
| Investing cash flow | ¥19m | 2024-06-01 → 2025-05-31 | Cons. | Net cash provided by used in investment activities |
| Investing cash flow | −¥1.1bn | 2023-06-01 → 2024-05-31v | Cons. | Net cash provided by used in investing activities (5-year summary) |
| Investing cash flow | −¥107m | 2022-06-01 → 2023-05-31v | Cons. | Net cash provided by used in investing activities (5-year summary) |
| Investing cash flow | −¥27m | 2021-06-01 → 2022-05-31v | Cons. | Net cash provided by used in investing activities (5-year summary) |
| Financing cash flow | −¥337m | 2025-06-01 → 2026-05-31 | Cons. | Net cash provided by used in financing activities |
| Financing cash flow | −¥240m | 2024-06-01 → 2025-05-31 | Cons. | Net cash provided by used in financing activities |
| Financing cash flow | −¥335m | 2023-06-01 → 2024-05-31v | Cons. | Net cash provided by used in financing activities (5-year summary) |
| Financing cash flow | −¥209m | 2022-06-01 → 2023-05-31v | Cons. | Net cash provided by used in financing activities (5-year summary) |
| Financing cash flow | −¥229m | 2021-06-01 → 2022-05-31v | Cons. | Net cash provided by used in financing activities (5-year summary) |
| EPS (basic) | ¥258.56 | 2025-06-01 → 2026-05-31 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥249.79 | 2024-06-01 → 2025-05-31 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥227.96 | 2023-06-01 → 2024-05-31v | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥85.83 | 2022-06-01 → 2023-05-31v | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥272.67 | 2021-06-01 → 2022-05-31v | Cons. | Basic earnings loss per share (5-year summary) |
| Net assets per share | ¥3,680.48 | at 2026-05-31 | Cons. | Net assets per share (5-year summary) |
| Net assets per share | ¥3,640.22 | at 2025-05-31 | Cons. | Net assets per share (5-year summary) |
| Net assets per share | ¥3,429.08 | at 2024-05-31v | Cons. | Net assets per share (5-year summary) |
| Net assets per share | ¥3,097.34 | at 2023-05-31v | Cons. | Net assets per share (5-year summary) |
| Net assets per share | ¥3,126.18 | at 2022-05-31v | Cons. | Net assets per share (5-year summary) |
| Equity ratio | 34.6% | at 2026-05-31 | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 32.6% | at 2025-05-31 | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 32.2% | at 2024-05-31v | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 32.2% | at 2023-05-31v | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 33.1% | at 2022-05-31v | Cons. | Equity to asset ratio (5-year summary) |
| ROE | 7.1% | 2025-06-01 → 2026-05-31 | Cons. | Rate of return on equity (5-year summary) |
| ROE | 7.0% | 2024-06-01 → 2025-05-31 | Cons. | Rate of return on equity (5-year summary) |
| ROE | 7.1% | 2023-06-01 → 2024-05-31v | Cons. | Rate of return on equity (5-year summary) |
| ROE | 2.8% | 2022-06-01 → 2023-05-31v | Cons. | Rate of return on equity (5-year summary) |
| ROE | 8.9% | 2021-06-01 → 2022-05-31v | Cons. | Rate of return on equity (5-year summary) |
| Employees | 617 | at 2026-05-31 | Cons. | Number of employees |
| Employees | 613 | at 2025-05-31 | Cons. | Number of employees |
| Employees | 606 | at 2024-05-31v | Cons. | Number of employees |
| Employees | 570 | at 2023-05-31v | Cons. | Number of employees |
| Employees | 574 | at 2022-05-31v | Cons. | Number of employees |
| Revenue | ¥1.5bn | 2025-06-01 → 2026-05-31 | Standalone | Operating revenue1 |
| Revenue | ¥1.4bn | 2024-06-01 → 2025-05-31 | Standalone | Operating revenue1 |
| Revenue | ¥1.4bn | 2023-06-01 → 2024-05-31v | Standalone | Operating revenue1 (5-year summary) |
| Revenue | ¥498m | 2022-06-01 → 2023-05-31v | Standalone | Operating revenue1 (5-year summary) |
| Revenue | ¥792m | 2021-06-01 → 2022-05-31v | Standalone | Operating revenue1 (5-year summary) |
| Operating income | ¥809m | 2025-06-01 → 2026-05-31 | Standalone | Operating income |
| Operating income | ¥729m | 2024-06-01 → 2025-05-31 | Standalone | Operating income |
| Ordinary income | ¥819m | 2025-06-01 → 2026-05-31 | Standalone | Ordinary income |
| Ordinary income | ¥728m | 2024-06-01 → 2025-05-31 | Standalone | Ordinary income |
| Ordinary income | ¥764m | 2023-06-01 → 2024-05-31v | Standalone | Ordinary income loss (5-year summary) |
| Ordinary income | −¥16m | 2022-06-01 → 2023-05-31v | Standalone | Ordinary income loss (5-year summary) |
| Ordinary income | ¥227m | 2021-06-01 → 2022-05-31v | Standalone | Ordinary income loss (5-year summary) |
| Profit before tax | ¥754m | 2025-06-01 → 2026-05-31 | Standalone | Income before income taxes |
| Profit before tax | ¥728m | 2024-06-01 → 2025-05-31 | Standalone | Income before income taxes |
| Net income | ¥740m | 2025-06-01 → 2026-05-31 | Standalone | Profit loss |
| Net income | ¥718m | 2024-06-01 → 2025-05-31 | Standalone | Profit loss |
| Net income | ¥767m | 2023-06-01 → 2024-05-31v | Standalone | Net income loss (5-year summary) |
| Net income | −¥13m | 2022-06-01 → 2023-05-31v | Standalone | Net income loss (5-year summary) |
| Net income | ¥228m | 2021-06-01 → 2022-05-31v | Standalone | Net income loss (5-year summary) |
| Total assets | ¥8.8bn | at 2026-05-31 | Standalone | Assets |
| Total assets | ¥8.5bn | at 2025-05-31 | Standalone | Assets |
| Total assets | ¥8.0bn | at 2024-05-31v | Standalone | Total assets (5-year summary) |
| Total assets | ¥6.3bn | at 2023-05-31v | Standalone | Total assets (5-year summary) |
| Total assets | ¥6.5bn | at 2022-05-31v | Standalone | Total assets (5-year summary) |
| Total liabilities | ¥1.3bn | at 2026-05-31 | Standalone | Liabilities |
| Total liabilities | ¥1.8bn | at 2025-05-31 | Standalone | Liabilities |
| Net assets / equity | ¥7.5bn | at 2026-05-31 | Standalone | Net assets |
| Net assets / equity | ¥6.8bn | at 2025-05-31 | Standalone | Net assets |
| Net assets / equity | ¥6.3bn | at 2024-05-31v | Standalone | Net assets |
| Net assets / equity | ¥5.8bn | at 2023-05-31v | Standalone | Net assets (5-year summary) |
| Net assets / equity | ¥6.0bn | at 2022-05-31v | Standalone | Net assets (5-year summary) |
| Cash and deposits | ¥328m | at 2026-05-31 | Standalone | Cash and deposits |
| Cash and deposits | ¥732m | at 2025-05-31 | Standalone | Cash and deposits |
| EPS (basic) | ¥295.55 | 2025-06-01 → 2026-05-31 | Standalone | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥291.15 | 2024-06-01 → 2025-05-31 | Standalone | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥301.31 | 2023-06-01 → 2024-05-31v | Standalone | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥-5.29 | 2022-06-01 → 2023-05-31v | Standalone | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥89.32 | 2021-06-01 → 2022-05-31v | Standalone | Basic earnings loss per share (5-year summary) |
| Dividend per share | ¥107 | 2025-06-01 → 2026-05-31 | Standalone | Dividend paid per share (5-year summary) |
| Dividend per share | ¥75 | 2024-06-01 → 2025-05-31 | Standalone | Dividend paid per share (5-year summary) |
| Dividend per share | ¥70 | 2023-06-01 → 2024-05-31v | Standalone | Dividend paid per share (5-year summary) |
| Dividend per share | ¥48 | 2022-06-01 → 2023-05-31v | Standalone | Dividend paid per share (5-year summary) |
| Dividend per share | ¥82 | 2021-06-01 → 2022-05-31v | Standalone | Dividend paid per share (5-year summary) |
| Net assets per share | ¥2,954.65 | at 2026-05-31 | Standalone | Net assets per share (5-year summary) |
| Net assets per share | ¥2,741.18 | at 2025-05-31 | Standalone | Net assets per share (5-year summary) |
| Net assets per share | ¥2,521.27 | at 2024-05-31v | Standalone | Net assets per share (5-year summary) |
| Net assets per share | ¥2,272.88 | at 2023-05-31v | Standalone | Net assets per share (5-year summary) |
| Net assets per share | ¥2,360.07 | at 2022-05-31v | Standalone | Net assets per share (5-year summary) |
| Equity ratio | 85.2% | at 2026-05-31 | Standalone | Equity to asset ratio (5-year summary) |
| Equity ratio | 79.2% | at 2025-05-31 | Standalone | Equity to asset ratio (5-year summary) |
| Equity ratio | 78.2% | at 2024-05-31v | Standalone | Equity to asset ratio (5-year summary) |
| Equity ratio | 92.2% | at 2023-05-31v | Standalone | Equity to asset ratio (5-year summary) |
| Equity ratio | 92.4% | at 2022-05-31v | Standalone | Equity to asset ratio (5-year summary) |
| ROE | 10.4% | 2025-06-01 → 2026-05-31 | Standalone | Rate of return on equity (5-year summary) |
| ROE | 11.0% | 2024-06-01 → 2025-05-31 | Standalone | Rate of return on equity (5-year summary) |
| ROE | 12.7% | 2023-06-01 → 2024-05-31v | Standalone | Rate of return on equity (5-year summary) |
| ROE | -0.2% | 2022-06-01 → 2023-05-31v | Standalone | Rate of return on equity (5-year summary) |
| ROE | 3.8% | 2021-06-01 → 2022-05-31v | Standalone | Rate of return on equity (5-year summary) |
| Shares issued | 2,553,000 | at 2026-05-31 | Standalone | Total number of issued shares (5-year summary) |
| Shares issued | 2,553,000 | at 2025-05-31 | Standalone | Total number of issued shares (5-year summary) |
| Shares issued | 2,553,000 | at 2024-05-31v | Standalone | Total number of issued shares (5-year summary) |
| Shares issued | 2,553,000 | at 2023-05-31v | Standalone | Total number of issued shares (5-year summary) |
| Shares issued | 2,553,000 | at 2022-05-31v | Standalone | Total number of issued shares (5-year summary) |
| Employees | 31 | at 2026-05-31 | Standalone | Number of employees |
| Employees | 30 | at 2025-05-31 | Standalone | Number of employees |
| Employees | 29 | at 2024-05-31v | Standalone | Number of employees |
| Employees | 30 | at 2023-05-31v | Standalone | Number of employees |
| Employees | 27 | at 2022-05-31v | Standalone | Number of employees |
Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.
Segments · 48
| Segment | Item | Period | Value |
|---|---|---|---|
| Reconciling Itemsreconciling | depreciation | 2025-06-01 → 2026-05-31 | ¥37m |
| Reconciling Itemsreconciling | revenue | 2025-06-01 → 2026-05-31 | −¥2m |
| Reconciling Itemsreconciling | revenue intersegment | 2025-06-01 → 2026-05-31 | −¥2m |
| Reconciling Itemsreconciling | segment profit | 2025-06-01 → 2026-05-31 | −¥1.2bn |
| Medical Equipment Manufacturing And Salesreportable segment | depreciation | 2025-06-01 → 2026-05-31 | ¥45m |
| Medical Equipment Manufacturing And Salesreportable segment | employees | at 2026-05-31 | 9 pure |
| Medical Equipment Manufacturing And Salesreportable segment | revenue | 2025-06-01 → 2026-05-31 | ¥210m |
| Medical Equipment Manufacturing And Salesreportable segment | revenue external | 2025-06-01 → 2026-05-31 | ¥207m |
| Medical Equipment Manufacturing And Salesreportable segment | revenue intersegment | 2025-06-01 → 2026-05-31 | ¥2m |
| Medical Equipment Manufacturing And Salesreportable segment | segment profit | 2025-06-01 → 2026-05-31 | −¥185m |
| Medical Equipment Salesreportable segment | depreciation | 2025-06-01 → 2026-05-31 | ¥117m |
| Medical Equipment Salesreportable segment | employees | at 2026-05-31 | 564 pure |
| Medical Equipment Salesreportable segment | revenue | 2025-06-01 → 2026-05-31 | ¥63.9bn |
| Medical Equipment Salesreportable segment | revenue external | 2025-06-01 → 2026-05-31 | ¥63.9bn |
| Medical Equipment Salesreportable segment | revenue intersegment | 2025-06-01 → 2026-05-31 | ¥0 |
| Medical Equipment Salesreportable segment | segment profit | 2025-06-01 → 2026-05-31 | ¥2.1bn |
| Medical Mallreportable segment | depreciation | 2025-06-01 → 2026-05-31 | ¥14m |
| Medical Mallreportable segment | revenue | 2025-06-01 → 2026-05-31 | ¥74m |
| Medical Mallreportable segment | revenue external | 2025-06-01 → 2026-05-31 | ¥74m |
| Medical Mallreportable segment | segment profit | 2025-06-01 → 2026-05-31 | ¥7m |
| —segment total | depreciation | 2025-06-01 → 2026-05-31 | ¥177m |
| —segment total | revenue | 2025-06-01 → 2026-05-31 | ¥64.2bn |
| —segment total | revenue external | 2025-06-01 → 2026-05-31 | ¥64.1bn |
| —segment total | revenue intersegment | 2025-06-01 → 2026-05-31 | ¥2m |
| —segment total | segment profit | 2025-06-01 → 2026-05-31 | ¥2.0bn |
| Reconciling Itemsreconciling | depreciation | 2024-06-01 → 2025-05-31 | ¥37m |
| Reconciling Itemsreconciling | revenue | 2024-06-01 → 2025-05-31 | ¥0 |
| Reconciling Itemsreconciling | revenue intersegment | 2024-06-01 → 2025-05-31 | ¥0 |
| Reconciling Itemsreconciling | segment profit | 2024-06-01 → 2025-05-31 | −¥1.1bn |
| Medical Equipment Manufacturing And Salesreportable segment | depreciation | 2024-06-01 → 2025-05-31 | ¥6m |
| Medical Equipment Manufacturing And Salesreportable segment | revenue | 2024-06-01 → 2025-05-31 | ¥219m |
| Medical Equipment Manufacturing And Salesreportable segment | revenue external | 2024-06-01 → 2025-05-31 | ¥219m |
| Medical Equipment Manufacturing And Salesreportable segment | revenue intersegment | 2024-06-01 → 2025-05-31 | ¥0 |
| Medical Equipment Manufacturing And Salesreportable segment | segment profit | 2024-06-01 → 2025-05-31 | −¥220m |
| Medical Equipment Salesreportable segment | depreciation | 2024-06-01 → 2025-05-31 | ¥122m |
| Medical Equipment Salesreportable segment | revenue | 2024-06-01 → 2025-05-31 | ¥64.2bn |
| Medical Equipment Salesreportable segment | revenue external | 2024-06-01 → 2025-05-31 | ¥64.2bn |
| Medical Equipment Salesreportable segment | revenue intersegment | 2024-06-01 → 2025-05-31 | ¥0 |
| Medical Equipment Salesreportable segment | segment profit | 2024-06-01 → 2025-05-31 | ¥2.2bn |
| Medical Mallreportable segment | depreciation | 2024-06-01 → 2025-05-31 | ¥14m |
| Medical Mallreportable segment | revenue | 2024-06-01 → 2025-05-31 | ¥72m |
| Medical Mallreportable segment | revenue external | 2024-06-01 → 2025-05-31 | ¥72m |
| Medical Mallreportable segment | segment profit | 2024-06-01 → 2025-05-31 | ¥5m |
| —segment total | depreciation | 2024-06-01 → 2025-05-31 | ¥143m |
| —segment total | revenue | 2024-06-01 → 2025-05-31 | ¥64.5bn |
| —segment total | revenue external | 2024-06-01 → 2025-05-31 | ¥64.5bn |
| —segment total | revenue intersegment | 2024-06-01 → 2025-05-31 | ¥0 |
| —segment total | segment profit | 2024-06-01 → 2025-05-31 | ¥2.0bn |
Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.
All source rows · 1,495
| Item | Context | Value | Unit |
|---|---|---|---|
| Reason for increase in number of shares shares not listed investment shares held for purposes other than pure investment largest holding company | CurrentYearDuration | － | |
| Reason for increase in number of shares shares other than those not listed investment shares held for purposes other than pure investment largest holding company | CurrentYearDuration | Original text (Japanese)事業関係の一層の強化 | |
| Name of securities details of specified investment equity securities held for purposes other than pure investment largest holding company | CurrentYearInstant_Row1Member | Original text (Japanese)テルモ株式会社 | |
| Purpose of shareholding overview of business alliance quantitative effects of shareholding and reason for increase in number of shares details of specified investment shares held for purposes other than pure investment largest holding company | CurrentYearInstant_Row1Member | Original text (Japanese)（保有目的及び株式数が増加した理由）取引関係維持・強化を目的として保有しています。（定量的な保有効果）注１ | |
| Whether issuer of aforementioned shares holds reporting companys shares details of specified investment shares held for purposes other than pure investment largest holding company | CurrentYearInstant_Row1Member | Original text (Japanese)無 | |
| Name of securities details of specified investment equity securities held for purposes other than pure investment largest holding company | CurrentYearInstant_Row2Member | Original text (Japanese)オリンパス株式会社 | |
| Purpose of shareholding overview of business alliance quantitative effects of shareholding and reason for increase in number of shares details of specified investment shares held for purposes other than pure investment largest holding company | CurrentYearInstant_Row2Member | Text · Plus | |
| Whether issuer of aforementioned shares holds reporting companys shares details of specified investment shares held for purposes other than pure investment largest holding company | CurrentYearInstant_Row2Member | Original text (Japanese)無 | |
| Footnotes specified investment shares held for purposes other than pure investment largest holding company (text) | CurrentYearInstant_Row1Member | Text · Plus | |
| Basic policy on human resources strategy employees etc (text) | FilingDateInstant | Text · Plus | |
| Information about employees (text) | FilingDateInstant | Text · Plus | |
| Consolidated subsidiaries metrics of consolidated subsidiaries | CurrentYearInstant_Row1Member | Original text (Japanese)山下医科器械株式会社 | |
| Regulations in accordance with which consolidated financial statements have been prepared financial information | CurrentYearDuration | Text · Plus | |
| Regulations in accordance with which financial statements have been prepared financial information | CurrentYearDuration | Text · Plus | |
| Note on independent audit financial information | CurrentYearDuration | Text · Plus | |
| Remarkable efforts to ensure fair presentation of consolidated financial statements etc financial information | CurrentYearDuration | Text · Plus | |
| Consolidated balance sheet (text) | CurrentYearDuration | Text · Plus | |
| Consolidated statement of income (text) | CurrentYearDuration | Text · Plus | |
| Consolidated statement of comprehensive income (text) | CurrentYearDuration | Text · Plus | |
| Consolidated statement of changes in equity (text) | CurrentYearDuration | Text · Plus | |
| Consolidated statement of cash flows (text) | CurrentYearDuration | Text · Plus | |
| Notes significant accounting policies for preparation of consolidated financial statements (text) | CurrentYearDuration | Text · Plus | |
| Number of consolidated subsidiaries and names of major consolidated subsidiaries (text) | CurrentYearDuration | Text · Plus | |
| Changes in scope of consolidation (text) | CurrentYearDuration | Text · Plus | |
| Number of unconsolidated subsidiaries and associates accounted for using equity method and names of major entities accounted for using equity method (text) | CurrentYearDuration | Text · Plus | |
| Disclosure about fiscal years etc of consolidated subsidiaries (text) | CurrentYearDuration | Text · Plus | |
| Disclosure of accounting policies (text) | CurrentYearDuration | Text · Plus | |
| Significant accounting estimates consolidated financial statements (text) | CurrentYearDuration | Text · Plus | |
| Notes new accounting standards not yet applied consolidated financial statements (text) | CurrentYearDuration | Text · Plus | |
| Notes changes in presentation consolidated financial statements (text) | CurrentYearDuration | Text · Plus | |
| Notes regarding amounts of notes and accounts receivable trade and contract assets (text) | CurrentYearInstant | Text · Plus | |
| Notes regarding amount of revenue from contracts with customers (text) | CurrentYearDuration | Text · Plus | |
| Research and development expenses included in general and administrative expenses and manufacturing cost for current period (text) | CurrentYearDuration | Text · Plus | |
| Notes regarding impairment loss (text) | CurrentYearDuration | Text · Plus | |
| Notes regarding loss on step acquisitions (text) | CurrentYearDuration | Text · Plus | |
| Notes regarding loss on sales of shares of subsidiaries (text) | CurrentYearDuration | Text · Plus | |
| Notes regarding reclassification adjustments income taxes and tax effects relating to other comprehensive income (text) | CurrentYearDuration | Text · Plus | |
| Notes regarding issued shares and treasury shares (text) | Prior1YearDuration | Text · Plus | |
| Notes regarding dividend (text) | Prior1YearDuration | Text · Plus | |
| Notes regarding issued shares and treasury shares (text) | CurrentYearDuration | Text · Plus | |
| Notes regarding dividend (text) | CurrentYearDuration | Text · Plus | |
| Reconciliation of ending balance of cash and cash equivalents with account balances per balance sheet (text) | CurrentYearDuration | Text · Plus | |
| Major components of assets and liabilities of consolidated subsidiary acquired by purchase of shares during reporting period (text) | CurrentYearDuration | Text · Plus | |
| Major components of assets and liabilities of consolidated subsidiary disposed of by sales of shares during reporting period (text) | CurrentYearDuration | Text · Plus | |
| Notes leases consolidated financial statements (text) | CurrentYearDuration | Text · Plus | |
| Notes financial instruments consolidated financial statements (text) | CurrentYearDuration | Text · Plus | |
| Notes securities consolidated financial statements (text) | CurrentYearDuration | Text · Plus | |
| Notes retirement benefits consolidated financial statements (text) | CurrentYearDuration | Text · Plus | |
| Notes tax effect accounting consolidated financial statements (text) | CurrentYearDuration | Text · Plus | |
| Notes asset retirement obligations consolidated financial statements (text) | CurrentYearDuration | Text · Plus |
Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.
Data checks · 24 of 24 passed
| balance sheet identity | pass rounding |
| balance sheet identity | pass rounding |
| balance sheet identity | pass rounding |
| balance sheet identity | pass |
| dei present | pass |
| period resolution | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · revenue | pass |
| statement vs summary · revenue | pass |
| statement vs summary · revenue | pass |
| statement vs summary · revenue | pass |
| statement vs summary · total assets | pass |
| statement vs summary · total assets | pass |
| statement vs summary · total assets | pass |
| statement vs summary · total assets | pass |